Judge Refuses To Review Amgen Case
Hoffman-La Roche (Roche) maintains that its drug, CERA, doesn’t infringe on any of Amgen’s patents for epoetin, a man-made version of human erythropoietin (EPO.)
The decisions don’t give Hoffman-La Roche the green light to manufacture and sell CERA, or pegylated recombinant human erythropoietin, in the United States. The ruling only allows Roche to import and...
To view the full article, register now.